Dataset Maps Lung Neuroendocrine Tumour Genomics

Researchers release a multi-omic dataset covering 294 lung neuroendocrine tumours from 201 participants.

Updated on Nov. 16, 2026 in Cancer

Dataset Maps Lung Neuroendocrine Tumour Genomics

Researchers have released a multi-omic dataset of lung neuroendocrine tumours, drawn from 294 tumours across 201 participants. The dataset combines RNA sequencing, methylation arrays, whole-genome sequencing, spatial proteomics, spatial transcriptomics and whole-slide histopathology images.

Why it matters

Recent studies left the genomic and morphological features of lung neuroendocrine tumours underexplored because whole-genome and imaging data were limited. The release offers a shared resource for further molecular and morphological analysis of these tumours, which make up roughly 2% of lung cancers.

The dataset draws on 294 tumours from 201 participants, with multi-regional whole-genome sequencing for 41 participants, spatial proteomics for 67 and spatial transcriptomics for 4, against a backdrop in which these tumours account for about 2% of lung cancers. Its clinical associations and outcome-linked findings have not yet been reported.

The players

IARC Computational Cancer Genomics team

The International Agency for Research on Cancer is the World Health Organization's cancer research arm, and its computational genomics team leads the Rare Cancers Genomics initiative that houses the lungNENomics project.

The details

Twelve centres voluntarily contributed one formalin-fixed, paraffin-embedded block per patient to the lungNENomics project, which is part of the Rare Cancers Genomics initiative led by the IARC Computational Cancer Genomics team. Samples were shared from biobanks in Lyon, Nice and Caen under authorisation from the French Ministry of Research.

Timeline

  1. November 16, 2026: The article describing the lung neuroendocrine tumour dataset was published.

Big Picture

The release extends the Rare Cancers Genomics initiative led by the IARC Computational Cancer Genomics team by adding a multi-omic resource specifically for lung neuroendocrine tumours. It fills a gap in whole-genome and imaging data that recent studies on these tumours had left underexplored.

For people affected by lung neuroendocrine tumours, the dataset is a research resource rather than a treatment, and it does not change current care. Its value to patients depends on whether downstream studies turn the genomic and imaging findings into clinical tools.

The takeaway

The dataset provides a shared foundation for studying a rare lung cancer subtype at the genomic and morphological level. Its usefulness will be shown by the analyses that researchers build on it in the coming years.

Further reading

Explore more on Cancer research and genomic studies.

Source note: This article includes information reported by Nature.